

PHILIPSBURY

JUL 19 1999

07/56977
Group Art Unit8/13/90
ExaminerPaper No. 16Assistant Commissioner for Patents
Washington, DC 20231I hereby request access under 37 CFR 1.14(a)(3)(iv) to the application file record of the above-identified ~~ABANDONED~~ application, which is: (CHECK ONE)

- ☐ (A) referred to in United States Patent Number 5623065 column
- ☐ (B) referred to in an application that is open to public inspection as set forth in 37 CFR 1.102
Application No. filed on page
paper number
- ☐ (C) an application that claims the benefit of the filing date of an application that is open to inspection, i.e., Application No. filed
- ☐ (D) an application in which the applicant has filed an authorization to lay open the entire application to the public.

Please direct any correspondence concerning this request to the following address:

Signature

Billy Mullenap

Typed or printed name

5/6/99
Date

FOR PTO USE ONLY

Approved by: [Signature]
(Ink)Unit:



United States Patent [19]

[11] Patent Number: 5,623,065

Cook et al.

[45] Date of Patent: Apr. 22, 1997

[54] GAPPED 2' MODIFIED
OLIGONUCLEOTIDES

[75] Inventors: Phillip D. Cook, Vista; Brett P. Monia,
Carlsbad, both of Calif.

[73] Assignee: Isis Pharmaceuticals, Inc., Carlsbad,
Calif.

[21] Appl. No.: 244,993

[22] PCT Filed: Dec. 23, 1992

[86] PCT No.: PCT/US92/11339

§ 371 Date: Jun. 21, 1994

§ 102(e) Date: Jun. 21, 1994

[87] PCT Pub. No.: WO93/11339

PCT Pub. Date: Jul. 8, 1993

Related U.S. Application Data

[63] Continuation-in-part of Ser. No. 814,961, Dec. 24, 1991,
abandoned, and Ser. No. 566,977, Aug. 13, 1990, aban-
doned.

[51] Int. Cl.⁶ C07H 21/00; C07H 21/02;
C07H 21/04

[52] U.S. Cl. 536/23.1; 536/23.2; 536/23.5;
536/23.51; 536/23.52; 536/23.53; 536/25.1;
536/25.2; 435/91.1; 435/91.2; 435/91.5;
935/6; 935/9; 935/10

[58] Field of Search 514/44; 536/23.1,
536/23.2, 23.5, 23.51, 23.52, 23.53, 25.1,
25.2; 435/91.1, 91.2, 91.4, 91.5; 935/9,
6, 10

[56] References Cited

U.S. PATENT DOCUMENTS

4,867,187	9/1989	Duck	435/6
4,908,307	3/1990	Rodland et al.	435/6
5,013,830	5/1991	Ohtsuka et al.	536/25.1
5,034,506	7/1991	Summerton et al.	528/391
5,134,066	7/1992	Rogers et al.	435/91.3
5,149,797	9/1992	Pederson et al.	536/23.1
5,220,007	6/1993	Pederson et al.	536/23.1
5,256,775	10/1993	Froehler	536/25.6
5,366,878	11/1994	Pederson et al.	435/91.3
5,403,711	4/1995	Walder et al.	435/6
5,466,786	11/1995	Buhr et al.	536/26.26

FOREIGN PATENT DOCUMENTS

2017369	11/1990	Canada
260032	8/1987	European Pat. Off.
365627B1	3/1989	European Pat. Off.
0339842	4/1989	European Pat. Off.
0339330	11/1990	European Pat. Off.
3915462	9/1990	Germany
4110085	10/1992	Germany
3-240795	of 1991	Japan
89/05358	6/1989	WIPO
WO90/15814	6/1990	WIPO
WO91/06556	10/1990	WIPO
WO91/15499	4/1991	WIPO
WO91/12323	8/1991	WIPO
WO94/02498	2/1994	WIPO
WO92/07065	9/1994	WIPO

OTHER PUBLICATIONS

Block et al. 1988 *Gene* 72, 349-360.

Cormier et al. 1988 *Nuc. Acids Res.* 16(10), 4583-4594.

Uhlmann et al. 1990 *Chemical Reviews* 90(4), 544-584.

Ikehara et al. 1977 *Nuc. Acids Res.* 4(12): 4249-4260.

Berkowitz et al. 1973 *J. Medicinal Chemistry*, 16(2):
813-814.

Kawasaki et al. 1991 (Jan.) "Synthesis and Biophysical
Studies of 2'-dRIBO-F Modified Oligonucleotides", Con-
ference on Nucleic Acid Therapeutics, Clearwater, FL.

Agrawal, S. et al., "Oligodeoxynucleoside Phosphorami-
dates and Phosphorothioates as Inhibitors of Human Immu-
nodeficiency Virus" *Proc. Natl. Acad. Sci. USA* 1988 85,
7079-7083.

Augustyns, et. al., "Influence of the Incorporation of
(S)-9-(3,4-dihydroxy-butyl)Adenine on the Enzymatic
Stability and Base-Pairing Properties of Oligodeoxynucle-
otides" *Nucleic Acids Research* 1991, 19, 2587-2593.

Beaton, et. al., Chapter 5, Synthesis of oligonucleotide
phosphorodithioates, p. 109, *Oligonucleotides and Analogs*,
A Practical Approach, Eckstein, F., Ed.; The Practical
Approach Series, IRL Press, New York, 1991, pp. 109-135.

Borthwick, et al., "Synthesis of Chiral Carbocyclic Nucleo-
sides", *Tetrahedron* 1992, 48, 571-623.

Brill et al., "Synthesis of Deoxydinucleoside Phospho-
rodithioates", *J. Am. Chem. Soc.* 1991 113, 3972-3980.

Cohen in *Oligonucleotides: Antisense Inhibitors of Gene
Expression*, CRC Press, Inc., Boca Raton, FL (1989), pp.
1-255.

Dagle et al., "Physical properties of oligonucleotides con-
taining phosphoramidate-modified internucleoside link-
ages", *Nucleic Acids Research* 1991 19, 1805-1810.

Dagle et al., "Targeted degradation of mRNA in *Xenopus*
oocytes and embryos directed by modified oligonucleotides:
studies of An2 and cyclin in embryogenesis", *Nucleic Acids
Research* 1990 18, 4751-4757.

Dagle et al., "Pathways of Degradation and Mechanism of
Action of Antisense Oligonucleotides in *Xenopus laevis*
Embryos", *Antisense Research and Development* 1991 1,
11-20.

Debart et al., "Intermolecular Radical C-C Bond Forma-
tion: Synthesis of a Novel Dinucleoside Linker for Non-an-
ionic Antisense Oligonucleosides", *Tetra. Ltrs.* 1992 33,
2645-2648.

(List continued on next page.)

Primary Examiner—Christopher S. F. Low

Attorney, Agent, or Firm—Woodcock Washburn Kurtz
Mackiewicz & Norris

[57] ABSTRACT

Oligonucleotides and other macromolecules are provided
that have increased nuclease resistance, substituent groups
for increasing binding affinity to complementary strand, and
subsequences of 2'-deoxy-erythro-pentofuranosyl nucle-
otides that activate RNase H enzyme. Such oligonucleotides
and macromolecules are useful for diagnostics and other
research purposes, for modulating protein in organisms, and
for the diagnosis, detection and treatment of other conditions
susceptible to antisense therapeutics.

19 Claims, 2 Drawing Sheets